The study also found that injecting the vaccine directly into the tumor led to greater immune cell activity within the tumor environment Representational image: National Cancer Institute
Medicine

Moffitt Study Finds Vaccine May Improve Breast Cancer Prognosis

The study enrolled 30 patients with stage 2 and stage 3 HER2-positive, ER-negative breast cancer who were undergoing chemotherapy before surgery to shrink the tumor.

MBT Desk

Moffitt Cancer Center [1] researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer [2] and has shown encouraging results in a recent pilot study. Published in npj Breast Cancer [3], the study combined the HER2-targeting dendritic cell vaccines with standard chemotherapy, demonstrating both safety and positive response rates.

The study enrolled 30 patients with stage 2 and stage 3 HER2-positive, ER-negative breast cancer who were undergoing chemotherapy before surgery to shrink the tumor. Researchers gave the HER2-directed dendritic cell vaccine before chemotherapy to determine its effects on immune response and treatment outcomes. The results showed that patients receiving the vaccine had significant immune activity, with complete tumor disappearance observed in a notable percentage of cases.

“Our findings suggest that the dendritic cell vaccine can boost the body’s immune response against tumors, potentially improving the effectiveness of chemotherapy,” said Hatem Soliman, M.D.[4], medical oncologist in the Breast Oncology Department [5]at Moffitt and lead author of the study. “This approach may offer a new way to enhance breast cancer treatment and patient outcomes.”

Breast cancer is the most common one diagnosed in woman worldwide.

The study also found that injecting the vaccine directly into the tumor led to greater immune cell activity within the tumor environment. This could help refine future immunotherapy strategies for breast cancer and other types of cancer.

“These findings highlight the potential of immunotherapy to transform how we treat HER2-positive breast cancer,” said Brian Czerniecki, M.D., Ph.D [6].

References:

1) http://moffitt.org/

2) https://www.moffitt.org/cancers/breast-cancer/

3) https://rdcu.be/edSso

4) https://www.moffitt.org/providers/hatem-soliman

5) https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/

6) https://www.moffitt.org/providers/brian-czerniecki/

(Newswise/TL)

Also read:UC Irvine Researchers Highlight Positive Trends in Anti-Diabetic Medication Use

Also Read

Study Reveals New Mechanisms Behind Common Mutation and Prostate Cancer

Community Comes Together to Bring Inpatient Rehabilitation to Tennessee Children

California Immigrants Weigh Health Coverage Against Deportation Risk

Siddaramaiah Links COVID Vaccine to Cardiac Deaths, Sparks National Backlash

Republican Megabill Will Mean Higher Health Costs for Many Americans